Roche's MabThera yields strong data in CLL
Early results from two Phase II trials tracking the outcome of patients with chronic lymphocytic leukemia treated with Roche's MabThera (rituximab) have shown promising results, according to the firm. The Swiss drug major presented data on the drug at the 49th annual meeting of the American Society of Hematology, in Atlanta.
In the first trial, 92% of patients with previously untreated CLL achieved a response when given MabThera in combination with chemotherapy. Roche noted that this improvement confirms similar results from earlier studies. Also being investigating is the impact of MabThera maintenance therapy in CLL patients, as all responding patients in the induction phase will also receive MabThera maintenance therapy. Results from the second part of the study are expected in 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze